between cannabis use and potential harms, such as risk of MDD and worsening of depression symptoms and outcomes. There is only minimal evidence in BD suggesting the harms of cannabis use, therefore, future controlled, prospective designs are necessary in furthering these primary findings. Considering anxiety disorders, additional longitudinal, prospective studies as well as controlled, clinical trials are necessary for determining any therapeutic potential of cannabinoids. Moreover, similarly as described in MDD and BD, future research is required to determine the specific harms that cannabis can induce in anxiety, as findings are currently mixed. Finally in PTSD, current trials reporting benefits of cannabis involve specific populations, such as exclusively male participants or military veterans, and very small sample sizes. Future controlled studies addressing these limitations are warranted. To better understand potential cannabis harms, longitudinal, prospective studies must be conducted to determine the exact association between cannabis use overtime in PTSD of which also addresses frequency, preparation and onset of cannabis use.
